Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

PHASE3TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 21, 2016

Primary Completion Date

October 16, 2017

Study Completion Date

November 6, 2017

Conditions
Erosive Esophagitis
Interventions
DRUG

Dexlansoprazole

Dexlansoprazole delayed-release capsules.

DRUG

Lansoprazole

Lansoprazole capsules.

DRUG

Placebo

Dexlansoprazole placebo-matching capsules.

Trial Locations (25)

20001

Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai

100032

Peking University First Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

110004

Shengjing Hospital of China Medical University, Shenyang

130000

The First Hospital of Jilin University, Changchun

210009

Zhongda Hospital Southeast, Nanjing

212001

Affiliated Hospital of Jiangsu University, Wuxi

214023

Wuxi people's hospital, Wuxi

250013

Jinan Central Hospital, Jinan

252000

Liaocheng Hospital, Liaocheng

256603

Binzhou Medical University Hospital, Binzhou

266003

The Affiliated Hospital of Qingdao University, Qingdao

300121

Tianjin People's Hospital, Tianjin

361004

Zhongshan Hospital Xiamen University, Xiamen

404100

Chongqing Three Gorges Central Hospital, Chongqing

410015

The Third Hospital of Changsha, Changsha

430000

Central Hospital of Wuhan, Wuhan

Puai Hospital Of Wuhan City, Wuhan

442000

Taihe Hospital, Shiyan

530022

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

570100

Affilicated Hospital of Guilin Medical University, Haikou

610041

West China Hospital,Sichuan University, Chengdu

050051

Hebei General Hospital, Shijiazhuang

030001

The First Hospital of Shanxi Medical University, Taiyuan

The Second Hospital of Shanxi Medical University, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY